when was the first glp 1 agonist approved Timeline of GLP-1 discovery and clinical development. (a) Key events in GLP-1 Medications for Weight Loss:

What to watch and what to do The next 18 months will substantially redraw this picture

Fasting leads to reduced microbiome-derived propionate production Short-chain fatty acids (SCFAs), which include propionate, are products of gut microbiome

Clinicians should monitor patients for potential adverse effects including pancreatitis (severe, persistent abdominal pain), gallbladder disease (right upper quadrant pain), diabetic retinopathy complications (especially with rapid glucose improvement), acute kidney injury with dehydration, and hypoglycemia when combined with insulin or sulfonylureas

Patient acceptability in terms of preferred treatment options as per real-world scenarios

Catto-Smith et al., 1989a,b)

D.ParkS.WalleniusV.LiuJ